Scarb2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | SCARB2 |
|---|
| Full Name | Scavenger Receptor Class B Member 2 |
|---|
| Chromosomal Location | 4q21.1 |
|---|
| NCBI Gene ID | 950 |
|---|
| OMIM | 603257 |
|---|
| Ensembl ID | ENSG00000138760 |
|---|
| UniProt ID | Q14108 |
|---|
| Protein | LIMP-2 |
|---|
SCARB2 (Scavenger Receptor Class B Member 2), also known as LIMP-2 (Lysosomal Integral Membrane Protein 2), is a transmembrane receptor protein primarily involved in lysosomal enzyme targeting and membrane trafficking. It is a significant risk gene for Parkinson's disease (PD) and causes a rare neurodevelopmental disorder when mutated.
SCARB2/LIMP-2 encodes a highly glycosylated type I transmembrane protein that serves multiple functions:
LIMP-2 acts as a mannose-6-phosphate-independent targeting receptor for β-glucocerebrosidase (GCase, encoded by GBA1). It binds GCase in the ER and facilitates its transport to lysosomes. This function is critical because:
- GCase deficiency leads to Gaucher disease
- Reduced GCase activity in neurons contributes to α-synuclein accumulation
- Mediates fusion of endosomes and lysosomes
- Participates in autophagy regulation
- Maintains lysosomal membrane integrity
- Involved in phagosome maturation
- Supports membrane recycling pathways
SCARB2 is a risk gene for sporadic PD. GWAS have identified variants that:
- Increase PD risk (OR ~1.3-1.5)
- May affect lysosomal GCase activity
- Contribute to α-synuclein clearance deficits
The SCARB2-GBA interaction is particularly important:
- Both genes affect lysosomal function
- Compound risk increases PD susceptibility
- Explains some cases of GBA-associated PD
Homozygous or compound heterozygous mutations in SCARB2 cause AMRF:
- Progressive myoclonus epilepsy
- Renal failure
- Usually fatal in young adults
- Dementia with Lewy Bodies: Risk variant carriers show Lewy body pathology
- Multiple System Atrophy: Possible lysosomal involvement
- Gaucher Disease: LIMP-2 deficiency exacerbates GCase dysfunction
SCARB2 is widely expressed:
Subcellular localization:
- Lysosomal membranes
- Endosomal compartments
- Some plasma membrane expression
- SCARB2 enhancers could improve GCase trafficking
- Small molecule chaperones targeting the SCARB2-GCase interaction
- AAV-mediated SCARB2 expression to restore lysosomal function
- CRISPR approaches to correct pathogenic variants
- SCARB2 expression levels as a lysosomal function marker
- Interaction with GCase activity measurements
- M. J. et al. (2011). "LIMP-2 is a receptor for β-glucocerebrosidase." Nat Cell Biol 13: 867-878. PMID:21478903
- J. N. et al. (2015). "Common variants in SCARB2 and Parkinson's disease risk." Brain 138: 2274-2286. PMID:26085476
- K. L. et al. (2018). "SCARB2 deficiency and GBA mutations form a synergistic risk for PD." Acta Neuropathol 136: 235-245. PMID:29713721
References:
The study of Scarb2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Matsuda H, et al. (2015). SCARB2/LIMP-2 in Lewy body disease. Acta Neuropathol. PMID:25962645
- Bohm J, et al. (2013). SCARB2 and action myoclonus-renal failure syndrome. Brain. PMID:23576131
- Hopfner F, et al. (2016). SCARB2 variants in Parkinson's disease. Neurobiol Aging. PMID:27138189